MiRNA Expression Profiling in Cisplatin Resistance Human Gastric Cancer Cell Lines and Their Parental Cell Lines
Cisplatin is the first-line agent utilized for the clinical treatment of a wide variety of solid tumors including gastric cancer. However, the intrinsic or acquired cisplatin resistance is often occurred in patients with gastric cancer and resulted in failure of cisplatin therapy. In order to investigate if miRNA involves in cisplatin resistance of human gastric cancer, we first screened and compared the expression of miRNAs between cisplatin resistant gastric cancer cell lines SGC-7901/DDP and...
Provenance — who produced it, who reused it
Linked to 3 papers in the literature. Roles are inferred factual signals (who deposited the data vs who reused it), with counts — never a judgement about any author.
- MicroRNA-148a-3p enhances cisplatin cytotoxicity in gastric canc... 2017 · 165 cites
- Circular RNA MCTP2 inhibits cisplatin resistance in gastric canc... 2020 · 93 cites
- MiR-99a and MiR-491 Regulate Cisplatin Resistance in Human Gastr... 2016 · 81 cites
Deep data QC
metadata only · no data-level QC for this typeStandardized, field-standard QC computed by touching the data — every metric states how it was obtained
No quantitative QC rubric exists for this data type yet, so it is deliberately left unscored — this is an honest "not applicable", not a poor rating.
measured = computed from the data · extrapolated/reported = derived or from the repository · dq-1.0 · provisional — verify independently